BioSpace News Archive

CytomX Therapeutics, Inc. announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2022 financial results will be released on Thursday, April 28, after the market closes.

Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.001 per share as of the close of market on April 25, 2022.

InVivo Therapeutics Holdings Corp. announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock.

As a fast growing Contract Research Orgnization (CRO) and clinical diagnostics laboratory, iCura Diagnostics has focused its services on advanced diagnostic techonologies such as multiplexing immunofluorescence (IF)/immunohistochemicstry (IHC), Circulating Tumor Cells (CTC), and genomic servcies to promote clinical trials, translational research, and clinica diagnosis.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of common stock (the “Common Stock”) at a public offering price of $0.85 per share.

The global central lab market was estimated at USD 2.6 Billion in 2021 and it is set to grow USD 4.2 Billion by 2030 with a modest CAGR of 6.1% during the prediction period 2022 to 2030.

Atomic Spectroscopy is the technique that is carried out for the determination the elements and its composition using electromagnetic or mass spectrum.